• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·603998.SS
Share

Hunan Fangsheng Pharmaceutical Co., Ltd. Stocks

CN¥ 9.92Last Updated 14.07.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

CN¥ 601.99M

CN¥ 9.92
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating within China, Hunan Fangsheng Pharmaceutical Co., Ltd. is engaged in the complete spectrum of pharmaceutical activities, from research and development to manufacturing and sales. Its diverse product line encompasses tablets, capsules, and granules, addressing a wide array of therapeutic areas such as cardiovascular, cerebrovascular, orthopedic, pediatric, gynecological, traumatology, and anti-infective conditions. The company was established in 2002 and is headquartered in Changsha, China.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7

The average target price of 603998.SS is 16.6 and suggests 70.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 17:30

Assets under management at BlackRock exceeded $15 trillion for the first time

15.07.2026 17:00

OpenAI's first device will be a "smart speaker." Will this create competition for Apple?

15.07.2026 16:35

The stock price of Stride, a small edtech company, has plummeted. The reason is Anthropic

15.07.2026 16:00

"There Aren't Enough IT Budgets to Go Around": What Does IBM's Historic Plunge Mean for the Stock Market?

15.07.2026 15:46

Morning in New York: New inflation data will set the tone for trading

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026